↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Medtronic$MDT · filed: grew revenue 8.4% in FY2026 to $36.4BNew shipTrillion Score 532Fall Risk LowNext year $35.1B–$40.3B sealedCheck ▾Close ▴
What Medtronic filed
Grew revenue 8.4% in FY2026 to $36.4 billion, operating margin 17.8% against a 7.5% median for electromedical & electrotherapeutic apparatus, equity 53.2% of assets, and dividend per share up 13 years running. Every figure links to the filing it came from on Medtronic’s card. New ship: no warning signs. Trillion Score 532, #42 of 116 in its field; Fall Risk Low (how it is measured).
What the house said in advance
Revenue for the fiscal year after 2026-04-24 between $35.1B and $40.3B, an 80% range sealed on 26 Sept 2026 · receipt #162bad · graded in public by the revenue in Medtronic’s next annual report.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
**$2.1B** liability shift via exchange offer; finalized ratio by April 22 reveals true MiniMed valuation versus Dexcom's **8.2x** sales.
$2.1 billion
in diabetes-device liabilities off the parent balance sheet
$5.3 billion
in tendered shares
2%-7%
discount to trailing volume-weighted average price
1.9x
trailing revenue based on the diabetes segment's last disclosed
Medtronic initiated an exchange offer for the separation of its MiniMed continuous glucose monitoring business, completing a spinoff structure that shifts roughly $2.1 billion in diabetes-device liabilities off the parent balance sheet. Shareholders can swap Medtronic ordinary shares for MiniMed common stock at a slight discount, with the company targeting completion by mid-Q2 2025.
The mechanics matter. Medtronic will accept up to $5.3 billion in tendered shares, exchanging them for the entirety of its MiniMed stake at an expected 2%-7% discount to trailing volume-weighted average price. The range signals willingness to adjust terms if demand lags, a feature absent in hard splits. MiniMed will assume $2.1 billion in debt and other obligations, capitalizing the new entity at approximately 1.9x trailing revenue based on the diabetes segment's last disclosed $2.8 billion in annual sales. The parent retains zero ownership post-close.
This cleanly isolates the continuous glucose monitor franchise from Medtronic's surgical robotics and cardiac rhythm businesses, each operating at materially different margin profiles. MiniMed's sub-18% EBITDA margin drags consolidated figures; Medtronic's surgical and neuromodulation units run above 28%. Separation allows MiniMed to compete with Dexcom and Abbott on dedicated R&D budgets without crossfire from cardiac implant pricing negotiations with CMS. The exchange structure is tax-efficient for the parent and dodges the dilution of an IPO, though it does transfer tail risk on product liability suits tied to insulin pump malfunction claims to holders who elect the swap.
Allocators should track three near-term catalysts. First, the exchange ratio will be finalized between April 18-22, giving a hard read on implied MiniMed valuation versus Dexcom's 8.2x sales multiple. Second, MiniMed's standalone S-1 amendment—expected by April 25—will disclose stand-alone cash flow, which Medtronic has not broken out in segmented filings since 2022. Third, any adjustment to the $2.1 billion debt assumption in the final terms signals either balance sheet concern or aggressive levering for bolt-on acquisitions in continuous monitoring software. Medtronic's treasury desk has already lined up a $1.2 billion term loan B for MiniMed, pricing 375 bps over SOFR, which implies a low-investment-grade credit view.
The exchange closes the week of May 12, assuming regulatory clearance. Medtronic shareholders holding as of April 14 record date can participate. The company has not disclosed minimum participation thresholds, which means it retains the option to pull the offer if uptake implies an unworkable float for MiniMed. That optionality is the tell.
Branded by POPS4 · proof in 60 seconds
For the principal
Track April 22 exchange ratio for valuation signal; MiniMed's standalone S-1 discloses never-before-broken cash flow by April 25.
For the operator
Watch $1.2B term loan B pricing at 375 over SOFR; low-grade implies bolt-on M&A capacity post-separation in CGM software.
For the house
We fade Medtronic parent post-split on margin expansion; consider MiniMed pair trade against Dexcom if ratio implies sub-7x sales.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.